References

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

10.1016/s2352-3026(20)30081-8 · 2020 · External reference

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

10.1056/nejmoa1606038 · 2016 · External reference

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

10.1016/s0140-6736(20)30734-0 · 2020 · External reference

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

10.1016/s1470-2045(21)00579-9 · 2022 · External reference

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

10.1038/s41375-020-0813-1 · 2020 · External reference

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

10.1016/s1470-2045(21)00128-5 · 2021 · External reference

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

10.1016/s2352-3026(23)00218-1 · 2023 · External reference

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

10.1038/leu.2011.196 · 2012 · External reference

Patient characteristics and survival outcomes of lenalidomide exposed non- refractory vs. lenalidomide refractory multiple myeloma patients in the HONEUR Federated Data Network

10.1182/blood-2022-159401 · 2022 · External reference

FDA analysis of racial demographics in multiple myeloma trials

2017 · External reference

Guidelines for determination of the number of prior lines of therapy in multiple myeloma

10.1182/blood-2015-05-647636 · 2015 · External reference

An introduction to inverse probability of treatment weighting in observational research

10.1093/ckj/sfab158 · 2022 · External reference

Comparisons of real-world time-to-event end points in oncology research

10.1200/cci.20.00125 · 2021 · External reference

Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR

10.1016/j.clml.2019.09.623 · 2020 · External reference

Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial

10.1200/jco.21.02734 · 2023 · External reference

Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma

10.1002/ajh.26074 · 2021 · External reference

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

10.1080/10428194.2022.2030477 · 2022 · External reference

Real-world outcomes with generic pomalidomide in relapsed refractory multiple myeloma-experience from a Tertiary Care Cancer Center

10.1200/go.20.00228 · 2021 · External reference

Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma

10.1158/1078-0432.ccr-19-1997 · 2020 · External reference

Once-weekly (70 mg/m(2)) vs twice-weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: a post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

10.1002/cam4.2945 · 2020 · External reference

Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN Nonrandomized Clinical Trial

10.1001/jamaoncol.2021.0611 · 2021 · External reference

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma

10.1200/jco.21.01935 · 2022 · External reference

Ide-cel or standard regimens in relapsed and refractory multiple myeloma

10.1056/nejmoa2213614 · 2023 · External reference